Evidence map›Paper›PMID 22453793›Full record

Trial reportSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2012

Immunonutrition before and during radiochemotherapy: improvement of inflammatory parameters in head and neck cancer patients.

Christelle Machon, Simon Thezenas, Anne-Marie Dupuy, Eric Assenat, Françoise Michel, Emilie Mas, Pierre Senesse, Jean-Paul Cristol

Registry-linked trialAbstract readClinical Trial, Phase II
PubMed Publisher
In one paragraph

Trial report in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04001543 (Double-blind Multicenter Phase III Trial Evaluating the Efficacy of an Oral Immunomodulatory Nutrient on Survival During Postoperative Concomitant Chemoradiotherapy in Head and Neck Squamous Cell Carcinoma), which is not on this map. Cited by 15 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 1 pooled it
2.5field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04001543 naactive not recruitingnot on this mapstarted 2019, after this paper: background citation

Double-blind Multicenter Phase III Trial Evaluating the Efficacy of an Oral Immunomodulatory Nutrient on Survival During Postoperative Concomitant Chemoradiotherapy in Head and Neck Squamous Cell Carcinoma (HNSCC)

TypeinterventionalSponsorInstitut du Cancer de Montpellier - Val d'AurelleRan2019 to 2026Enrolled27ConditionsHead and Neck Squamous Cell CarcinomaArmsImmunomodulating oral supplementation, Sip feed control
3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 1 synthesis or guideline pooled it, 40 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Nutritional Issues in Head and Neck Cancer Patients.Healthcare (Basel, Switzerland) · 2020
    Review
  12. Article
  13. Article
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Christelle MachonDepartment of Biochemistry, Lapeyronie Hospital, 371 Avenue du Doyen Gaston Giraud, 34295 Montpellier Cedex 5, France.
Simon Thezenas
Anne-Marie Dupuy
Eric Assenat
Françoise Michel
Emilie Mas
Pierre Senesse
Jean-Paul Cristol
Hôpital Lapeyronie · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeInflammatory, angiogenic and oxidative stress markers have been explored in head and neck squamous cell carcinoma (HNSCC) patients before and during radiochemotherapy. Furthermore, the effects of an oral supplementation containing amino acids, ω-3 fatty acids, ribonucleic acids, vitamins, and antioxidants on biological markers and acute toxicities were investigated.

methodsThirty-one patients with non-metastatic stage III or IV HNSCC treated with concomitant radiochemotherapy were recruited. A nutritional support (Oral Impact) was given during 5 days before each cycle of chemotherapy. Biological samples were collected at baseline, after 5 days of oral supplementation and before the last cycle of chemotherapy. Acute phase proteins levels, proteomic cytokines determination and urinary isoprostanes levels were used as inflammatory and oxidative stress biomarkers. Toxicities were followed up during radiochemotherapy.

resultsAt baseline, median levels of inflammatory (CRP 9.8 mg/l [0.8-130.1], IL-6 4.2 pg/ml [0.7-126.5]), pro-angiogenic (VEGF 229.5 pg/ml [13.1-595.9]) and pro-oxidative stress (urinary isoprostanes 118 pmol/mmol creatinine [51-299]) markers were increased. Decrease in CRP (p = 0.002) and α-1 acid glycoprotein (p = 0.020) levels were observed after 5 days of oral supplementation. During radiochemotherapy, no significant variation of inflammatory markers was reported, and a low incidence of severe acute mucositis was noted.

conclusionsStage III or IV HNSCC patients are characterised by a pro-inflammatory, pro-angiogenic and pro-oxidative status. Nutritional support could improve this inflammatory state and could prevent severe acute mucositis.

Indexed as

Acute-Phase ProteinsAdultAgedAntioxidantsBiomarkersCarcinoma, Squamous CellChemoradiotherapyCytokinesDietary SupplementsFatty Acids, Omega-3FemaleHead and Neck NeoplasmsHumansInflammationIsoprostanesMaleAcute-Phase ProteinsAntioxidantsBiomarkersCytokinesFatty Acids, Omega-3IsoprostanesRNAVitamins

Identifiers

PMID22453793
OpenAlexW1966254339

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.